. 2022 Jul 29;37(8):849–870. doi: 10.1007/s10654-022-00896-z

Table 5.

Collected number of respective biosamples until April 03, 2022.

		Total	SUEP	HAP	POP
Patients with biosamples		4349	1442	439	2469
Visits with biosampling		8845	3915	2445	2485
Follow-up visits total		2920	754	346	1822
3 months		740	583	155	2
6 months		1942	3	120	1819
12 months		209	166	43	0
24 months		29	0	28	1
Average visit with biosampling per patient		2	3	6	1
	Intended use
EDTA blood	Plasma: proteome, metabolome, biomarker analysis; DNA: genome, epigenome	10,988	3974	2470	4544
Serum	Clinical and biomarker analysis	8636	3760	2435	2443
Respiratory sample^a	Determination of virus subtype, microbiome	7077	3644	950	2483
Oro/nasopharyngeal swab^a		2916	2358	468	90
Saliva^a		4091	1217	482	2392
ENTA^a,b		65	64	0	1
BAL^a,b		5	5	0	0
PAXgene RNA	Transcriptome	8362	3627	2407	2328
Citrate blood	Analysis of coagulation factors, biomarkers	10,727	4187	2470	4070
PBMC (all variants)	Analysis of cellular immune response	11,484	4701	4361	2422
CPT		5918	3337	936	1645
EDTA		1139	632	507	0
Heparine		4427	732	2918	777
Urine^a	Metabolome, kidney measures	6358	3055	959	2344

BAL, Bronchoalveolar lavage; ENTA, endotracheal aspiration; PBMC, peripheral blood mononuclear cells; CPT, cell preparation tube; SUEP, cross-sectoral platform; HAP, high-resolution platform; POP, population-based platform

^aOnly one sample taken per week

^bOnly for intensive care patients and clinical indication